Reference
Imai H, et al. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. Investigational New Drugs 40: 1066-1079, No. 5, Oct 2022. Available from: URL: http://doi.org/10.1007/s10637-022-01269-9
Rights and permissions
About this article
Cite this article
Amrubicin. Reactions Weekly 1928, 33 (2022). https://doi.org/10.1007/s40278-022-25298-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-25298-7